Article Text

Download PDFPDF

PS1:22 Use of interferon alpha and interleukin-10 as clinical activity biomarkers in systemic lupus erythematous patients
  1. E Grau1,
  2. M Fernandez Matilla2,
  3. CM Feced Olmos1,
  4. E Labrador Sanchez1,
  5. FM Ortiz Sanjuan1,
  6. N Fernandez-Llanio Cornella2,
  7. I Chalmeta Verdejo1,
  8. K Arevalo Ruales1,
  9. R Negueroles Albuixech1,
  10. J Ivorra Cortes1,
  11. JJ Fragio Gil1,
  12. I Martinez Cordellat1,
  13. R Gonzalez Mazario1,
  14. L Gonzalez Puig1,
  15. C Alcañiz Escandell1,
  16. C Najera Herranz1,
  17. I Canovas Olmos1,
  18. E Vicens Bernabeu1,
  19. JE Oller Rodriguez1,
  20. M de la Rubia Navarro1,
  21. JA Castellano Cuesta2,
  22. V Fornes Ferrer3,
  23. D Hervas Marin3 and
  24. JA Roman Ivorra1
  1. 1Rheumatology Department. HUP La Fe, Valencia, Spain
  2. 2Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain
  3. 3Biostatistics Unit. IIS La Fe, Valencia, Spain


Purpose To analyse the association among INF1A, IL10 and BLyS levels and clinical activity in SLE.

Methods A cross-sectional, observational study of 142 patients diagnosed of SLE according to SLICC 2012 criteria and 34 healthy controls was performed. In patients a complete blood-test was made, and clinical data by personal interview was collected. We analysed the serum concentration of IL10, BLyS and INF1A by colorimetric methods. SLE patients were dichotomized as high and low levels for each cytokine based on the cytokine level above 2 SD of the mean in healthy controls. Biostatistical analysis with R (3.3.2.) was performed.

Results In our SLE patients we observed higher values of IL10, BLyS and INF1A than healthy controls (p<0.001, p=0.005 and p=0.043 respectively), showing an average values in patients of 13.39±27.73 pg/mL INF1A, 9.99±15.84 pg/mL IL10 and 1811.31±1757.81 pg/mL BLyS. The mean clinical activity measured by SLEDAI was 5.91±5.06.

Statistical analysis indicate that INF1A levels are correlated to IL10 levels (p=0.001) and BLyS levels (p=0,034). Due to this finding, we categorised SLE patients by low or high level of the three cytokines: 44 INF1A(-)IL10(-)BLyS(-); 61 INF1A(+)IL10(-)BLyS(-); 5 INF1A(+)IL10(-)BLyS(+); 18 INF1A(+)IL10(+)BLyS(-) and 14 INF1A(+)IL10(+)BLyS(+). There is a high association of increased IL10-INF1A levels and the increased of clinical activity measured by SLEDAI score (p<0.0001), and to a lesser extent with increased IL10-INF1A-BLyS levels. Patients with high IL10-INF1A and IL10-INF1A-BLyS showed a significant rise in C3-C4 consumption (p<0.001 and p=0.001 respectively) and high anti-dsDNA (p=0.001 and p=0.002 respectively). Patients with increased INF1A-BLyS exhibited high anti-dsDNA (p=0.004) and ENA positivity (p<0.001). In addition, patients with increased levels of IL10-INF1A-BLyS showed ANAs (p<0.001) and antiphospholipid autoantibody positivity (p=0.004).

Conclusions The 69% of our SLE patients displayed almost one cytokine increased, being the INF1A the cytokine that mainly is increased. However, increased IL10 levels, irrespective of whether there is also increased levels of BLyS and/or INF1A, is the cytokine which best fits to clinical activity in SLE.

  • Interferon Alpha
  • Interleukin-10
  • Clinical Activity

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.